Predict your next investment

Verax Biomedical company logo
HEALTHCARE | Medical Devices & Equipment / Other Medical Devices
veraxbiomedical.com

See what CB Insights has to offer

Founded Year

1999

Stage

Loan | Alive

Total Raised

$72.43M

Last Raised

$680K | 2 yrs ago

About Verax Biomedical

Verax Biomedical is the producer of the Platelet PGD Test, a test for bacterial contamination in platelets granted a Safety Measure claim by the FDA. The test can be used to extend the dating of apheresis platelets in plasma, the most common platelet type transfused in the U.S., from 5 to 7 days. This dating extension offers the opportunity for significant cost savings to the blood banking community while preserving a critical life giving resource.

Verax Biomedical Headquarter Location

148 Bartlett Street

Marlborough, Massachusetts, 01752,

United States

+1 508 755 7029

Latest Verax Biomedical News

Verax Biomedical Signs Exclusive Agreement with Fisher Healthcare for Distribution of Platelet PGD® Test in U.S.

Aug 19, 2019

Fisher Healthcare is a major supplier of healthcare products to thousands of hospitals throughout the United States August 19, 2019 10:51 AM Eastern Daylight Time MARLBOROUGH, Mass.--( BUSINESS WIRE )--Verax Biomedical today announced that it has signed an exclusive agreement with Fisher Healthcare , a large healthcare laboratory product distributor, authorizing the company to distribute its Platelet PGD® Test through its channel in the U.S. The agreement with Fisher Healthcare comes as Verax prepares for expected FDA guidance on bacterial risk mitigation strategies for platelets. This move optimally positions Verax to serve its rapidly growing base of hospital users. “We’re extremely pleased that Fisher Healthcare will make our PGD Test available through its channel,” said Jim Lousararian, CEO of Verax. “Their hospital customers have been asking them for the ability to purchase PGD through their established distribution channel and this will dramatically increase our footprint in the U.S., allowing us to better serve our growing base of customers.” Fisher Healthcare maintains a large sales force of account executives who call on customers across the U.S. that will now complement Verax’s own sales force. The agreement with Fisher Healthcare represents a shift from Verax’s previous distributor, Fenwal / Freesnius Kabi , whose primary sales force focused on blood centers. The Platelet PGD Test is designed to detect bacterial contamination in platelets and is optimally used on the day of transfusion in the hospital transfusion service setting. By shifting distribution to a dominant hospital-focused distributor in advance of expected FDA final guidance, Verax will be able to quickly access and serve a rapidly expanding customer base. The PGD Test is FDA cleared as a Safety Measure, enabling its users to extend platelet dating from 5 to 7 days . Over 15 percent of platelets outdate annually in the U.S. at considerable cost to the healthcare system. PGD users who extend platelet dating with PGD report saving an average of over $200,000 annually through reduced platelet discards. About Verax Biomedical Verax is the producer of the Platelet PGD® Test , the only rapid test for bacterial contamination in platelets granted a Safety Measure claim by the FDA. The test can be used to extend the dating of apheresis platelets in plasma, the most common platelet type transfused in the U.S., from 5 to 7 days. This dating extension offers the opportunity for significant cost savings to the hospital and blood banking community while preserving a critical life-giving resource. For more information, visit www.veraxbiomedical.com . About Fisher Healthcare Fisher Healthcare is part of Thermo Fisher Scientific , the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. It focuses on helping its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Verax Biomedical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verax Biomedical is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,891 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Verax Biomedical Patents

Verax Biomedical has filed 3 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunologic tests
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/7/2013

Bacteriology, Immunologic tests, Bacteria, Microbiology, Analytical chemistry

Application

Application Date

10/7/2013

Grant Date

Title

Related Topics

Bacteriology, Immunologic tests, Bacteria, Microbiology, Analytical chemistry

Status

Application

Verax Biomedical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Verax Biomedical Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.